Key facts
- This page summarizes Jasper van Grunsven's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Sep 2026, 16:31.
Jasper van Grunsven - 08 Sep 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- EVP, CP and NPPO
- Issuer ticker
- VRTX
- Reported as of
- 08 Sep 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Christiana Stevenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jasper van Grunsven filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 10 Sep 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002154061
Primary reporting owner
van Grunsven Jasper
- Relationship
- EVP, CP and NPPO
- Address
- C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
- Signature
- /s/ Christiana Stevenson, Attorney-in-Fact
- Signature date
- 10 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Award
- Transaction value
- Shares
- +8,682
- Change %
- Price
- $0.000000*
- Shares after
- 8,682
- Date
- 08 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Restricted stock unit award that vests in installments beginning on 09/08/2027.